AT9283

Item no.	HY-50514-5mg
Manufacturer	MedChem Express
CASRN	896466-04-9
Amount	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 25 mg 2 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neural Transcription Factors Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Heart & Blood Cancer Lymphatic System Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.70
Formula	C19H23N7O2
Citations	bioRxiv. 2025 February 21. Cancers (Basel). 2022 Mar 19;14(6):1575. Harvard Medical School LINCS LIBRARY J Adv Res. 2023 Mar 7;S2090-1232(23)00070-X. Patent. US20180263995A1. PLoS One. 2024 Nov 1;19(11):e0308647. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Front Oncol. 2021 Jun 18;11:656608. PLoS Pathog. 2022 Jun 13;18(6):e1010620. [1]Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388. [2]Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. [3]Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71
Smiles	O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC=C(C=C4N3)CN5CCOCC5
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	896466-04-9
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Aurora Kinase; Autophagy; Bcr-Abl; FLT3; JAK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	381.43
Product Description	AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO : ≥ 100 mg/mL
Manufacturer - Pathway	Apoptosis; Autophagy; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Isoform	Abl; Aurora A; Aurora B; JAK2; JAK3
Clinical information	Phase 3

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-50514-5mg-safety-datasheet.pdf